Skip to content

In Dispute with Amgen, Sandoz Strikes Up Another Victory for Biosim Compatriots

Loeb & Loeb partner Mark Waddell is quoted on whether the Federal Circuit Court of Appeals’ new decision about violations of the “patent dance” will create more patent litigation. This article discusses the decision that ruled that branded drugmakers can't use state law to force biosim developers to disclose patent information under the Biologics Price Competition and Innovation Act (BPCIA).

Click here to read the article on FirercePharma’s website.